Technical Analysis for RENE - Reneuron Group Plc

Grade Last Price % Change Price Change
C 137.5 3.38% 4.50
RENE closed up 3.38 percent on Friday, April 16, 2021, on 17 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up
Historical RENE trend table...

Date Alert Name Type % Chg
NR7 Range Contraction 0.00%
Upper Bollinger Band Walk Strength 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Upper Bollinger Band Walk Strength 3.38%
Multiple of Ten Bearish Other 3.38%
Wide Bands Range Expansion 3.38%
Upper Bollinger Band Touch Strength 3.38%
Pocket Pivot Bullish Swing Setup -2.48%
Upper Bollinger Band Walk Strength -2.48%
Older End-of-Day Signals for RENE ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
No Alerts Yet. Alerts will only show here if at least one person is tracking alerts on this stock.
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Reneuron Group Plc Description

ReNeuron Group plc is a clinical-stage company. The Company, through its subsidiaries, is engaged in researching and developing cell-based therapies. The Company's products are allogeneic. Its CTX stem cell therapy is used for the treatment of patients left disabled by the effects of a stroke. Its human retinal progenitor cells (hRPC) stem cell candidate is used for the treatment of retinitis pigmentosa (RP). Its second CTX stem cell candidate is for the treatment of critical limb ischaemia. The Company's exosomes nanomedicine platform focuses on generating early pre-clinical data in cancer. Its ReNcell Products include ReNcellVM and ReNcellCX cell lines. It is engaged in Phase II clinical trial of CTX cells for stroke disability. It is engaged in Phase I clinical trial of CTX cells for Critical Limb Ischaemia. It is engaged in Phase I clinical trial of hRPC stem cell candidate. The Company has completed pre-clinical trials CTX-derived exosomes.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Research Biotechnology Medicine Clinic Life Sciences Earl Cancer Branches Of Biology Therapy Clinical Trial Biology Emerging Technologies Therapies Cell Therapy Nanomedicine Stem Cells Stroke Cell Biology

Is RENE a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 173.5
52 Week Low 70.0
Average Volume 193,908
200-Day Moving Average 105.35
50-Day Moving Average 115.08
20-Day Moving Average 123.03
10-Day Moving Average 129.60
Average True Range 8.51
ADX 30.72
+DI 26.68
-DI 12.27
Chandelier Exit (Long, 3 ATRs ) 121.88
Chandelier Exit (Short, 3 ATRs ) 127.52
Upper Bollinger Band 142.89
Lower Bollinger Band 103.16
Percent B (%b) 0.86
BandWidth 32.30
MACD Line 7.06
MACD Signal Line 5.14
MACD Histogram 1.9184
Fundamentals Value
Market Cap 45.01 Million
Num Shares 32.7 Million
EPS 0.50
Price-to-Earnings (P/E) Ratio 275.00
Price-to-Sales 354.97
Price-to-Book 4.07
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 145.00
Resistance 3 (R3) 145.00 142.50 143.75
Resistance 2 (R2) 142.50 140.59 142.50 143.33
Resistance 1 (R1) 140.00 139.41 138.75 140.00 142.92
Pivot Point 137.50 137.50 136.88 137.50 137.50
Support 1 (S1) 135.00 135.59 133.75 135.00 132.08
Support 2 (S2) 132.50 134.41 132.50 131.67
Support 3 (S3) 130.00 132.50 131.25
Support 4 (S4) 130.00